Organogenesis Apligraf
This article was originally published in The Gray Sheet
Executive Summary
Novartis Pharma is set to resume shipments of the bi-layered, living skin substitute under an agreement announced Nov. 20. Novartis suspended its distribution in September after the companies failed to agree on an amended arrangement ("1The Gray Sheet" Sept. 30, 2002, In Brief). Under the new arrangement, the licensing and distribution rights to Apligraf will revert to Organogenesis in June 2003. Subject to approval of a Boston bankruptcy court, the deal is part of a Chapter 11 reorganizing plan filed by Organogenesis in September...
You may also be interested in...
Organogenesis
Return of Apligraf bi-layered, living skin substitute to the market will be sought under a chapter 11 bankruptcy reorganization plan filed Sept. 25 in Boston federal court. An exclusive distribution pact with Novartis was terminated earlier this month when the parties failed to agree on an amended arrangement (1"The Gray Sheet" Sept. 16, 2002, In Brief). The Canton, Massachusetts firm's workforce was subsequently cut from 125 to 15...
Cochlear’s Osia System Receives Expanded FDA Clearance For Use In Younger Children
Kids ages 5 and up now can benefit from Cochlear’s Osia implant and sound processor, indicated for hearing loss, mixed hearing loss and single-sided sensorineural deafness.
MAISI: Navigating The 'Valley Of Death' In Medtech Research Translation
Translating research from proof of concept to clinical investigations is a difficult hurdle to overcome. To succeed, researchers need to design their technology for industrial standard manufacturing early on, Anne Vanhoestenberghe, director for the Manufacture of Active Implants and Surgical Instruments (MAISI), told Medtech Insight.